Literature DB >> 14511196

Migraine: diagnosis and management.

P J Goadsby1.   

Abstract

Migraine is the most common form of disabling primary headache and affects approximately 12% of studied Caucasian populations. Non-pharmacological management of migraine largely consists of lifestyle advice to help sufferers avoid situations in which attacks will be triggered. Preventive treatments for migraine should usually be considered on the basis of attack frequency, particularly its trend to change with time, and tract-ability to acute care. Acute care treatments for migraine can be divided into non-specific treatments (general analgesics, such as aspirin or non-steroidal anti--inflammatory drugs) and treatments relatively specific to migraine (ergotamine and the triptans). The triptans--sumatriptan, naratriptan, rizatriptan, zolmitriptan, almotriptan, eletriptan and frovatriptan--are potent serotonin, 5-HT1B/1D, receptor agonists which represent a major advance in the treatment of acute migraine. Chronic daily headache in association with analgesic overuse is probably the major avoidable cause of headache disability in the developed world.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14511196     DOI: 10.1046/j.1445-5994.2003.00453.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  5 in total

1.  The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with migraine without aura.

Authors:  Shahir Mazaheri; Mehrdad Hajilooi; Alireza Rafiei
Journal:  J Neurol       Date:  2006-10-24       Impact factor: 4.849

Review 2.  A possible role for mitochondrial dysfunction in migraine.

Authors:  S Stuart; L R Griffiths
Journal:  Mol Genet Genomics       Date:  2012-10-07       Impact factor: 3.291

Review 3.  The cerebellum and migraine.

Authors:  Maurice Vincent; Nouchine Hadjikhani
Journal:  Headache       Date:  2007-06       Impact factor: 5.887

4.  Possible association between dysfunction of vitamin D binding protein (GC Globulin) and migraine attacks.

Authors:  Eiichiro Nagata; Natsuko Fujii; Kazuyoshi Hosomichi; Shigeki Mitsunaga; Yoichi Suzuki; Yoichi Mashimo; Hideo Tsukamoto; Tadayuki Satoh; Motoki Osawa; Ituro Inoue; Akira Hata; Shunya Takizawa
Journal:  PLoS One       Date:  2014-08-22       Impact factor: 3.240

5.  Sublingual Delivery of Frovatriptan: An Indication of Potential Alternative Route.

Authors:  Hitesh Verma; Surajpal Verma; Shyam Baboo Prasad; Harmanpreet Singh
Journal:  Int Sch Res Notices       Date:  2014-10-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.